Rafael A. Rodriguez, a director at Neogen Corp, has reported a transaction involving 1,776 shares of the company's common stock. This filing is significant as it reflects ongoing executive activity and ownership changes within the company, which may impact investor perceptions and company dynamics.

Background

Neogen Corp, identified by the Central Index Key (CIK) 0000711377, operates in the in vitro and in vivo diagnostic substances sector. The company is incorporated in Michigan and has a fiscal year ending on May 31. Neogen is known for its focus on life sciences, particularly in providing solutions for food and animal safety.

What the Filing Says

In the recent filing dated October 30, 2026, Rodriguez reported acquiring 1,776 shares at a price of $12.21 each on October 29, 2026. The filing states, "Each RSU is the economic equivalent of one share of common stock. On October 29, 2026, these RSUs vested and were settled for an equal number of shares of common stock." Following this transaction, Rodriguez holds 31,211 shares of Neogen Corp.

Impact

This transaction may affect investors and stakeholders in Neogen Corp, as it reflects the ongoing involvement of its directors in the company's equity. Changes in ownership by directors can influence investor confidence and market perceptions, particularly in the competitive landscape of life sciences.

What's Next

The filing does not say what happens next.